MedTrace Logo

The Value of Surgical Mediastinal Staging in Clinical N1 Lung Cancer

NCT02222194 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 105

Last updated 2017-07-25

No results posted yet for this study

Summary

In case of PET or CT based cN1 (suspected) NSCLC, ESTS guidelines propose mediastinal staging by echo-endoscopy OR mediastinoscopy. Recent data show a sensitivity of less than 50% for echo-endoscopy to detect N2 disease in cN1 NSCLC patients, while prevalence of mediastinal nodal disease was 24% (unpublished data Aster II).2 The investigators plan to perform a prospective multicentric observational study to measure the sensitivity of mediastinal staging by video-assisted mediastinoscopy (VAM) in cN1 operable and resectable (suspected) NSCLC patients.

Conditions

  • Non Small Cell Lung Cancer

Sponsors & Collaborators

  • Johnny Moons

    lead OTHER

Principal Investigators

  • Herbert Decaluwé, MD · Universitaire Ziekenhuizen KU Leuven

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2017-03-31
Completion
2017-05-30

Countries

  • Belgium
  • France
  • Germany
  • Spain
  • Switzerland
  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02222194 on ClinicalTrials.gov